跳至主要内容
临床试验/NCT05481359
NCT05481359已完成不适用

A Post Market, Global Registry to Evaluate the Identification of Atrial Fibrillation Sources Using Electrographic Flow (EGF™) Mapping System to Guide Ablation Therapy in Patients With Atrial Fibrillation in Real-world Setting.

Ablacon, Inc.5 个研究点 分布在 3 个国家目标入组 25 人开始时间: 2022年9月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Ablacon, Inc.
入组人数
25
试验地点
5
主要终点
Number of Participants With Acute Procedure Success

研究概览

简要总结

This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.

详细描述

The AF-FLOW Registry is a prospective, multi-center global post-market registry that will obtain clinical data in order to characterize the performance of Electrographic Flow (EGF™) mapping with Ablamap® Software for its intended use in a real-world setting. Specifically, we will evaluate the ability of EGF mapping to identify sources of atrial fibrillation (AF) and guide ablation therapy in patients with atrial fibrillation. This registry will enroll up to 100 subjects. Subjects that present with AF and meet inclusion/exclusion criteria will be eligible for enrollment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Suitable candidate for intra-cardiac mapping and ablation of arrhythmias.
  • Above eighteen (18) years of age or of legal age to give informed consent specific to state and national law.
  • Subjects with a history of documented symptomatic atrial fibrillation.

排除标准

  • Subjects who are not candidates for cardiac ablation procedures.
  • Pregnant or nursing.
  • Presence of anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or comply with follow-up requirements.

结局指标

主要结局

Number of Participants With Acute Procedure Success

时间窗: During the procedure

Acute Procedure Success is defined as targeting and successful elimination of significant sources of electrographic flow (EGF) through radiofrequency ablation. EGF-identified sources are significant when their leading source activity is ≥ 26%. Successful elimination is defined as reduction of the source activity of the leading source to \<26% upon post-ablation remapping using EGF mapping.

次要结局

  • Number of Participants With 12-month Freedom From AF Recurrence(90 day - 12 months)

研究者

发起方
Ablacon, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验

AF-FLOW Registry to Evaluate Electrographic Flow... | 临床试验